CL2020001686A1 - Compuestos inhibidores del blanco mecanístico de rapamicina (mtor). - Google Patents
Compuestos inhibidores del blanco mecanístico de rapamicina (mtor).Info
- Publication number
- CL2020001686A1 CL2020001686A1 CL2020001686A CL2020001686A CL2020001686A1 CL 2020001686 A1 CL2020001686 A1 CL 2020001686A1 CL 2020001686 A CL2020001686 A CL 2020001686A CL 2020001686 A CL2020001686 A CL 2020001686A CL 2020001686 A1 CL2020001686 A1 CL 2020001686A1
- Authority
- CL
- Chile
- Prior art keywords
- inhibitor compounds
- mtor
- mechanistic target
- rapamycin
- rapamycin mechanistic
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 3
- 101150097381 Mtor gene Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 title 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 title 1
- 229960002930 sirolimus Drugs 0.000 title 1
- 229940124302 mTOR inhibitor Drugs 0.000 abstract 2
- 239000003628 mammalian target of rapamycin inhibitor Substances 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 239000003814 drug Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/20—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
La invención se relaciona con nuevos compuestos inhibidores de mTOR. Se caracteriza porque los compuestos inhibidores de mTOR son de la fórmula general (I). También se relaciona con composiciones que los comprenden, sus métodos de preparación y sus usos en composiciones como medicamento.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR1771402A FR3075795A1 (fr) | 2017-12-21 | 2017-12-21 | Nouveaux composes inhibiteurs de mtor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2020001686A1 true CL2020001686A1 (es) | 2020-11-27 |
Family
ID=62017455
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2020001686A CL2020001686A1 (es) | 2017-12-21 | 2020-06-19 | Compuestos inhibidores del blanco mecanístico de rapamicina (mtor). |
Country Status (16)
| Country | Link |
|---|---|
| US (1) | US11518767B2 (es) |
| EP (1) | EP3727390B1 (es) |
| JP (1) | JP2021506917A (es) |
| KR (1) | KR20200103032A (es) |
| CN (1) | CN111918654A (es) |
| AU (1) | AU2018392761B2 (es) |
| BR (1) | BR112020012201A2 (es) |
| CA (1) | CA3086243A1 (es) |
| CL (1) | CL2020001686A1 (es) |
| FR (1) | FR3075795A1 (es) |
| IL (1) | IL275531B2 (es) |
| MX (1) | MX2020006436A (es) |
| RU (1) | RU2020123899A (es) |
| SA (1) | SA520412289B1 (es) |
| SG (1) | SG11202005868XA (es) |
| WO (1) | WO2019122065A1 (es) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110407703A (zh) * | 2019-08-02 | 2019-11-05 | 深圳振强生物技术有限公司 | 吲哚布芬杂质的制备方法 |
| EP4370517B1 (en) | 2021-07-12 | 2025-12-24 | Galderma Holding SA | Synthesis of chiral substituted pyrazolopyrimidine compounds |
| WO2023031738A1 (en) | 2021-08-31 | 2023-03-09 | Galderma Holding SA | Novel mtor inhibitor compounds |
| WO2025113627A1 (zh) * | 2023-11-30 | 2025-06-05 | 武汉人福创新药物研发中心有限公司 | 含杂环的tead抑制剂 |
| TW202543630A (zh) * | 2024-03-06 | 2025-11-16 | 中國大陸商再鼎醫藥（上海）有限公司 | 作為ｔｅａｄ抑制劑的螺環化合物 |
| CN120774920A (zh) * | 2024-04-08 | 2025-10-14 | 浙江大学 | PI3Kδ-mTOR双靶点抑制剂及其制备方法和应用 |
| GB202415232D0 (en) | 2024-10-16 | 2024-11-27 | Nacamed As | Composition |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06002997A (es) | 2003-09-18 | 2007-02-08 | Conforma Therapeutics Corp | Novedosos compuestos heterociclicos como inhibidores- hsp90. |
| ES2365869T3 (es) * | 2005-11-17 | 2011-10-11 | OSI Pharmaceuticals, LLC | COMPUESTOS BICÍCLICOS FUSIONADOS INHIBIDORES DE LA mTOR. |
| CA2705303A1 (en) | 2007-11-07 | 2009-05-14 | Foldrx Pharmaceuticals, Inc. | Modulation of protein trafficking |
| EP2276763A1 (en) | 2008-03-19 | 2011-01-26 | OSI Pharmaceuticals, Inc. | Mtor inhibitor salt forms |
| US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
| JP6047149B2 (ja) * | 2011-05-04 | 2016-12-21 | インテリカイン， エルエルシー | 併用の医薬組成物およびその使用 |
| JP6122420B2 (ja) * | 2011-05-06 | 2017-04-26 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 多発性嚢胞疾患の治療 |
| KR20140084130A (ko) * | 2011-10-07 | 2014-07-04 | 셀좀 리미티드 | Mtor 억제제로서의 모르폴리노 치환된 바이사이클릭 피리미딘 우레아 또는 카르바메이트 유도체 |
| JP6130391B2 (ja) | 2011-11-23 | 2017-05-17 | インテリカイン， エルエルシー | Ｍｔｏｒ阻害剤を使用する強化された治療レジメン |
| CA2833701A1 (en) * | 2013-11-19 | 2015-05-19 | Pharmascience Inc. | Protein kinase inhibitors |
| EP3448866B1 (en) * | 2016-04-29 | 2020-06-17 | Merck Patent GmbH | Materials for organic electroluminescent devices |
| FR3075794A1 (fr) | 2017-12-21 | 2019-06-28 | Galderma Research & Development | Nouveaux composes inhibiteurs de mtor |
-
2017
- 2017-12-21 FR FR1771402A patent/FR3075795A1/fr not_active Ceased
-
2018
- 2018-12-20 BR BR112020012201-7A patent/BR112020012201A2/pt not_active IP Right Cessation
- 2018-12-20 MX MX2020006436A patent/MX2020006436A/es unknown
- 2018-12-20 AU AU2018392761A patent/AU2018392761B2/en not_active Expired - Fee Related
- 2018-12-20 EP EP18826025.1A patent/EP3727390B1/fr active Active
- 2018-12-20 SG SG11202005868XA patent/SG11202005868XA/en unknown
- 2018-12-20 JP JP2020534447A patent/JP2021506917A/ja not_active Ceased
- 2018-12-20 WO PCT/EP2018/086074 patent/WO2019122065A1/fr not_active Ceased
- 2018-12-20 KR KR1020207020410A patent/KR20200103032A/ko not_active Ceased
- 2018-12-20 CA CA3086243A patent/CA3086243A1/en active Pending
- 2018-12-20 CN CN201880090046.3A patent/CN111918654A/zh active Pending
- 2018-12-20 RU RU2020123899A patent/RU2020123899A/ru unknown
- 2018-12-20 IL IL275531A patent/IL275531B2/en unknown
-
2020
- 2020-06-19 US US16/907,122 patent/US11518767B2/en active Active
- 2020-06-19 CL CL2020001686A patent/CL2020001686A1/es unknown
- 2020-06-21 SA SA520412289A patent/SA520412289B1/ar unknown
Also Published As
| Publication number | Publication date |
|---|---|
| FR3075795A1 (fr) | 2019-06-28 |
| WO2019122065A1 (fr) | 2019-06-27 |
| RU2020123899A3 (es) | 2022-02-17 |
| SG11202005868XA (en) | 2020-07-29 |
| RU2020123899A (ru) | 2022-01-21 |
| SA520412289B1 (ar) | 2022-07-28 |
| MX2020006436A (es) | 2020-09-17 |
| US11518767B2 (en) | 2022-12-06 |
| US20200317683A1 (en) | 2020-10-08 |
| EP3727390A1 (fr) | 2020-10-28 |
| AU2018392761A1 (en) | 2020-07-09 |
| IL275531B1 (en) | 2023-05-01 |
| JP2021506917A (ja) | 2021-02-22 |
| CA3086243A1 (en) | 2019-06-27 |
| AU2018392761B2 (en) | 2023-09-14 |
| CN111918654A (zh) | 2020-11-10 |
| EP3727390B1 (fr) | 2023-03-22 |
| BR112020012201A2 (pt) | 2020-11-24 |
| IL275531B2 (en) | 2023-09-01 |
| IL275531A (en) | 2020-08-31 |
| KR20200103032A (ko) | 2020-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2020001686A1 (es) | Compuestos inhibidores del blanco mecanístico de rapamicina (mtor). | |
| CL2020001687A1 (es) | Nuevos compuestos inhibidores del blanco mecanístico de rapamicina (mtor). | |
| CO2021005987A2 (es) | Compuestos de anillo fusionado | |
| ECSP20033467A (es) | Compuestos macrocíclicos para tratar enfermedades | |
| CO2017011851A2 (es) | Compuestos novedosos | |
| SV2018005794A (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| CO2018004124A2 (es) | Compuestos heterocíclicos | |
| CO2018007528A2 (es) | Compuestos heterocíclicos como inmunomoduladores | |
| CR20190566A (es) | Inhibidores de quinasay usos de los mismos | |
| CR20170384A (es) | Derivados de nucleosidos sustituidos utiles como agentes antineoplasicos | |
| MX2018006148A (es) | Inhibidores de cxcr2. | |
| DOP2017000298A (es) | Reguladores de nrf2 | |
| DOP2017000078A (es) | Indazoles sustituidos con bencilo como inhibidores de bub1. | |
| MX385082B (es) | Compuestos de heteroarilo como inhibidores de tirosina-cinasa de bruton (btk) y usos de estos. | |
| MX383707B (es) | Compuestos de heteroarilo como inhibidores de cinasas asociadas a receptor de interleucina-1 (irak) y usos de los mismos. | |
| DOP2015000270A (es) | Potenciador de inhibidores del homólogo de zeste | |
| EA201692143A1 (ru) | Производные аминопиразина в качестве ингибиторов фосфатидилинозитол-3-киназы | |
| MX2016015565A (es) | Ciertos inhibidores de la proteina quinasa. | |
| NI201700029A (es) | Compuestos y composiciones como inhibidores de quinasa raf. | |
| MX2018002383A (es) | Composiciones farmaceuticas liquidas que comprenden inhibidores de sglt-2. | |
| BR112018011526A2 (pt) | compostos policíclicos como inibidores da tirosina quinase de bruton | |
| MX2017014459A (es) | Compuestos de tioeter como inhibidores de la nitrificacion. | |
| MX2019007336A (es) | Polimorfos. | |
| BR112017012005A2 (pt) | compostos orgânicos | |
| JO3793B1 (ar) | مثبطات تيروزين كاينيز بروتون وأساليب استخدامها |